Frankfurt - Delayed Quote EUR

PTC Therapeutics, Inc. (BH3.F)

42.80

-0.80

(-1.83%)

As of 8:15:58 AM GMT+1. Market Open.

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

PR Newswire 13 days ago

PTCT
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the 43rd Annual J.P. Morgan Healthcare Conference today at 11:15 a.m. PST / 2:15 p.m. EST. The presentation will be webcast live on the Events and Presentations page under the Investors section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 da

PR Newswire 13 days ago

PTCT
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST.

PR Newswire last month

PTCT
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA).

PR Newswire last month

PTCT
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.

Investor's Business Daily last month

PTCT

QURE
PTC Therapeutics price target raised to $71 from $47 at UBS

UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at closing and is eligible for up to $1.9B in development, regulatory and sales milestones, the analyst tells investors in a research note. PTC is a high conviction call into 2025, where UBS sees PTC a

TipRanks last month

NVS

NVSEF

PTCT
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.

Zacks last month

NVS

PTCT

OLMA
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Zacks last month

PTCT

NVS

SPRO
Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTC Therapeutics is set to obtain an upfront payment of $1bn.

Pharmaceutical Technology last month

NVS

PTCT
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Investor's Business Daily last month

NVS

NVSEF

PTCT
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires last month

PTCT

SNTI

NVS
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales. Also Read: FDA Grants Conditional Approval For PTC Therapeut

Benzinga last month

PTCT

NVS
PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.

Investopedia last month

PTCT

NVS
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

A groundbreaking drug, a massive deal, and a stock rally--this could reshape neurodegenerative disease treatments.

GuruFocus.com last month

NVS

PTCT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals wo

PREMIUM
MT Newswires last month

PTCT

NVS
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.

PR Newswire last month

NVS

NVSEF

PTCT
Novartis wagers billions of dollars on PTC Huntington’s drug

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.

BioPharma Dive last month

NVS

PTCT
PTC Therapeutics to sell Priority Review Voucher for $150M

PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M upon the closing of the transaction. PTC was granted the PRV on November 13 along with the U.S. FDA approval of KEBILIDI for the treatment of children and adults with AADC deficiency, including the full spectrum of disease severity. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Ha

TipRanks last month

PTCT
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis drug failed to halt disease progression.

Clinical Trials Arena last month

PTCT
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

On Tuesday, PTC Therapeutics Inc (NASDAQ:PTCT) revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients. The study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis. Also Read: FDA Grants Conditional Approval For PTC Therapeutics’ Gene Therapy As First Ever With Direct Administration In Brain While modest numerical benefit was recorded on the primary endpoint,

Benzinga last month

PTCT

Performance Overview

Return	BH3.F	S&P 500
YTD	0.00%	+3.29%
1-Year	+94.55%	+24.74%
3-Year	+17.58%	+40.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PTC Therapeutics, Inc. (BH3.F)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

PTC Therapeutics price target raised to $71 from $47 at UBS

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Sector Update: Health Care Stocks Slipping Late Afternoon

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Novartis wagers billions of dollars on PTC Huntington’s drug

PTC Therapeutics to sell Priority Review Voucher for $150M

PTC Therapeutics ALS drug fails to meet endpoints as trials shut down

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Performance Overview